Inactive Instrument

Nutriband Inc Stock Other OTC

US67092M1099

Medical Equipment, Supplies & Distribution

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	58.71M 50.31M 47.14M 43.06M 81.27M 5.6B 82.07M 556M 216M 2.82B 220M 216M 9.35B	P/E 2025	-8.39x	P/E 2026	-1.86x
Enterprise Value	54.38M 46.6M 43.67M 39.89M 75.28M 5.18B 76.02M 515M 201M 2.62B 204M 200M 8.66B	EV / Sales 2025	41.1x	EV / Sales 2026	26.5x
Free-Float	43.12%	Yield 2025 *	-	Yield 2026	-

06-12	Nutriband Inc. Reports Earnings Results for the First Quarter Ended April 30, 2026	CI
06-01	Nutriband Inc. announced that it has received $5 million in funding	CI
05-15	Active Intelligence and Nutriband Inc. Showcases Expanding Ai Wellness Product Portfolio and Announces New June Product Launches At Ecrm Conference	CI
04-30	Nutriband Inc. Reports Earnings Results for the Full Year Ended January 31, 2026	CI
03-18	Nutriband Ai Kinesiology Tapes Approves for Distribution and Sale in Costa Rica	CI
03-18	Nutriband Ai kinesiology tapes approved for distribution and sale in Costa Rica	RE
02-17	Nutriband Signs Exclusive Distribution Agreement with Innomedica for Aversa Fentanyl and All Sports Tape Products for Costa Rica	CI
02-17	Nutriband signs exclusive distribution agreement with Innomedica for Aversa fentanyl	RE
02-13	EarthVision Bio Solutions Inc. cancelled the acquisition of 90% stake in Pocono Pharmaceuticals, Inc. from Nutriband Inc..	CI
02-03	Nutriband Inc. Announces Election of New Directors	CI
01-31	Nutriband Inc.'s Equity Buyback announced on September 18, 2024, has expired.	CI
12-29	EarthVision Bio Solutions Inc. signed an agreement to acquire 90% stake in Pocono Pharmaceuticals, Inc. from Nutriband Inc. for $5 million.	CI
12-18	Nutriband signs letter of intent with Qvanta Group of Companies	RE

08-13	Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight	GL
05-15	Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference	GL
04-30	Nutriband : Annual Report for Fiscal Year Ending January 31, 2026 (Form 10-K)	PU
04-22	Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast	GL
03-31	Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch	GL

Manager	Title	Age	Since
Gareth Sheridan CEO	Chief Executive Officer	35	01/01/2016
Serguei Melnik CEO	Chief Executive Officer	52	-
Gerald Goodman DFI	Director of Finance/CFO	77	02/09/2020

Director	Title	Age	Since
Serguei Melnik CHM	Chairman	52	21/01/2022
Stefan Mancas BRD	Director/Board Member	48	01/07/2018
Mark Hamilton BRD	Director/Board Member	38	01/07/2018

Nutriband Inc Stock Other OTC

Stocks

US67092M1099

Medical Equipment, Supplies & Distribution

Valuation: Nutriband Inc

Latest news : Nutriband Inc

Press Releases: Nutriband Inc

Managers and Directors: Nutriband Inc

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NUTRIBAND INC	-.--%	-.--%	-	-	58.71M
ABBOTT LABORATORIES	-0.46%	+3.06%	-11.94%	+11.44%	201B
MEDTRONIC PLC	-1.89%	-1.03%	-0.98%	+10.89%	117B
CENCORA, INC.	+1.33%	+3.77%	+13.79%	+82.78%	62.6B
HOYA CORPORATION	-0.12%	-1.77%	+29.62%	+56.62%	52.49B
BECTON, DICKINSON AND COMPANY	-0.50%	+4.98%	-2.50%	-32.22%	51.69B
DEXCOM, INC.	-2.09%	-0.49%	+17.38%	-11.51%	33.65B
MEDLINE INC.	+2.71%	+4.45%	-	-	31.27B
WEST PHARMACEUTICAL SERVICES, INC.	-1.37%	+0.55%	+40.97%	-11.49%	24.52B
TERUMO CORPORATION	-0.94%	+4.05%	-2.80%	+19.77%	24.05B
Average	-0.33%	+1.39%	+10.44%	+15.78%	66.43B
Weighted average by Cap.	-0.51%	+1.53%	+2.29%	+17.41%

	2025	2026
Net sales	2.14M 1.83M 1.72M 1.57M 2.96M 204M 2.99M 20.26M 7.89M 103M 8.03M 7.86M 341M	2.04M 1.75M 1.64M 1.49M 2.82M 194M 2.85M 19.29M 7.51M 97.96M 7.65M 7.48M 324M
Net income	-10.48M -8.98M -8.42M -7.69M -14.51M -999M -14.65M -99.28M -38.65M -504M -39.36M -38.5M -1.67B	-8.23M -7.05M -6.61M -6.04M -11.39M -785M -11.5M -77.94M -30.34M -396M -30.9M -30.23M -1.31B
Net Debt	-4.13M -3.54M -3.31M -3.03M -5.71M -393M -5.77M -39.07M -15.21M -198M -15.49M -15.15M -657M	-4.33M -3.71M -3.48M -3.18M -5.99M -413M -6.05M -41M -15.96M -208M -16.26M -15.9M -690M